COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00335868
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : June 12, 2006
Last Update Posted : December 18, 2013
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: PHA-739358 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well PHA-739358 works in treating patients with chronic myelogenous leukemia that relapsed after imatinib mesylate or c-ABL therapy.

Condition or disease Intervention/treatment Phase
Leukemia Drug: danusertib Other: laboratory biomarker analysis Other: pharmacological study Phase 2

Detailed Description:


  • Explore the clinical efficacy of PHA-739358, in terms of hematological response lasting ≥ 4 weeks, in patients with chronic myelogenous leukemia that relapsed after imatinib mesylate or c-ABL therapy.
  • Explore the safety profile of this drug in these patients.
  • Explore the pharmacokinetic profile of this drug and its N-oxide metabolite PHA-816359 in plasma.
  • Explore the modulation of histone H3 and CRKL phosphorylation after PHA-739358 administration.
  • Explore the relationship between plasma drug levels and the modulation of histone H3 and CRKL phosphorylation.
  • Explore the clinical efficacy of this drug, in terms of cytogenetic response in bone marrow.
  • Explore response depending on status of T315I mutation in BCR-ABL kinase.

OUTLINE: This is a pilot, open-label, multicenter study.

Patients receive PHA-739358 IV over 6 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients benefitting from treatment may receive additional courses at the discretion of the investigator.

Patients undergo blood collection and bone marrow biopsies periodically for pharmacologic and biomarker correlative studies.

After completion of study treatment, patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 16 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Phase II Study of PHA-739358 in Patients With Chronic Myeloid Leukemia Relapsing on Gleevec or c-ABL Therapy
Study Start Date : March 2007
Estimated Primary Completion Date : December 2009

Primary Outcome Measures :
  1. Antileukemic response in terms of complete hematological response, no evidence of leukemia, or return to chronic phase
  2. Overall safety profile of PHA-739358 by type, severity, timing, and relatedness of adverse events and laboratory abnormalities
  3. Pharmacokinetics of this drug and its N-oxide metabolite PHA-816359 by measuring their plasma concentration at different times after dosing
  4. Changes in histone H3 and CRKL phosphorylation
  5. Correlation between changes in degree of histone H3 and CRKL phosphorylation and concurrent PHA-739358 concentrations and/or hematological response
  6. Complete, partial, or minor cytogenetic response in bone marrow

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of chronic myelogenous leukemia confirmed by bone marrow biopsy

    • Chronic, accelerated, or blastic phase disease
  • May have T315I mutation in BCR-ABL kinase
  • Relapsed after prior imatinib mesylate or c-ABL therapy
  • No CNS leukemia


  • ECOG performance status 0-2
  • Blood pressure ≤ 140/90 mm Hg (with or without hypertension treatment for ≥ 1 week)
  • Transaminases ≤ 2.5 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN
  • Creatinine ≤ 1.5 times ULN
  • No known history of HIV infection
  • No active uncontrolled infection
  • No grade 3 or 4 bleeding
  • LVEF ≥ 45% by MUGA or ≥ 40% by transthoracic echocardiography
  • No medical or psychiatric condition or laboratory abnormalities that would limit study compliance or increase risk during study participation
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 90 (female) or 180 (male) days after completion of study treatment
  • No significant cardiovascular disease (i.e., uncontrolled arrhythmias or unstable angina) within the past 6 months
  • No major thromboembolic event within the past 6 months, including any of the following:

    • Myocardial infarction
    • Stroke
    • Transient ischemic attack
    • Pulmonary embolism
    • Noncatheter-related deep-vein thrombosis


  • Recovered from all acute toxic effects (excluding alopecia) of prior therapy
  • More than 2 weeks since prior chemoimmunotherapy

    • Hydroxyurea must be discontinued 1 day prior to study therapy
  • More than 4 weeks since prior major surgery
  • No other concurrent approved or investigational anticancer treatment, including chemotherapy, biologic response modifiers, hormones, or immunotherapy
  • No other concurrent investigational drugs
  • No concurrent participation in another treatment clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00335868

Layout table for location information
United States, California
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Ronald Paquette, MD Jonsson Comprehensive Cancer Center
Layout table for additonal information
Responsible Party: Ronald Paquette, Jonsson Comprehensive Cancer Center at UCLA Identifier: NCT00335868    
Other Study ID Numbers: CDR0000486219
First Posted: June 12, 2006    Key Record Dates
Last Update Posted: December 18, 2013
Last Verified: July 2009
Keywords provided by National Cancer Institute (NCI):
accelerated phase chronic myelogenous leukemia
blastic phase chronic myelogenous leukemia
chronic phase chronic myelogenous leukemia
relapsing chronic myelogenous leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases